Company intelligence / Profile preview

FluxWear

Santa Ana, California, United States

Ownership: Private
Development stage: Other

Overview

SHIFT, FluxWear's wearable neuromodulation device, is commercially available for pain and anxiety, has received FDA Class I registration, and is being evaluated in clinical trials for neuropathic pain and post-concussive disorder. Prior studies reported efficacy rates of over 60% reduction in pain and anxiety in users. The company targets FDA Breakthrough Device status following these clinical studies.[1][2][4]

Therapeutic areas: OncologyNeurologyPsychiatry
Modalities: DevicePulsed electromagnetic field therapy
Industry: Therapeutic Medical Devices

Partnerships

HoagChildren's Hospital of Orange County (CHOC)

Beyond the preview

Go deeper on FluxWear.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FluxWear.

Explore the full profile